The nation's employers added more jobs than expected in November but the markets closed lower with the Dow losing 24 points to 15,889. Nasdaq edged up a fraction to 4038.
On the upside
A Seeking Alpha contributor wrote that Dataram (Nasdaq: DRAM) stock would climb.
A Seeking Alpha article said that Tonix Pharmaceutical (Nasdaq: TNXP) was undervalued and had tremendous upside potential.
Idera Pharmaceuticals (Nasdaq: IDRA) opened enrollment for a Phase 1/2 clinical trial of IMO-8400.
On the downside
The Centers for Medicare and Medicaid Services lowered its reimbursement for remote cardiac monitoring services which sent shares of BioTelemetry (Nasdaq: BEAT) tumbling.
Shares of FreeSeas (Nasdaq: FREE) continued falling after announcing a 5-for-1 reverse stock split on Monday.
Ambit Biosciences (Nasdaq: AMBI) must conduct a Phase 3 study of quizartinib before submitting a New Drug Application to the Food and Drug Administration.
In the broad market, declining issues outpaced advancers by a margin of nearly 5 to 3 on the NYSE and by 7 to 5 on Nasdaq. The broader S&P 500 slipped 2 points to 1792. Bitcoin climbed $18.05 or 1.50% to $1,223.10.
